查詢結果分析
相關文獻
- Serological Response to Helicobacter Pylori Infection Evaluated by Immunoblot Assay in Health Adults, Patients with Non-Ulcer Dyspepsia, Peptic Ulcer Disease, and Gastric Cancer
- 漫談幽門螺旋桿菌感染及基層醫療之對策
- New One-Week, Low-Dose Triple Therapy for the Treatment of Duodenal Ulcer with Helicobacter Pylori Infection
- A Multicenter Study on Eradication of Helicobacter pylori Infection in Patients with Duodenal Ulcer by Lansoprazole-Antibiotics Combined Therapy
- 消化性潰瘍的元兇--幽門螺旋桿菌
- 大黃抑制幽門螺旋桿菌及其作用機轉之研究
- 醇提大黃對消化性潰瘍合併幽門螺旋桿菌感染之作用探討
- 胃幽門螺旋桿菌的微生物學與流行病學
- 胃幽門螺旋桿菌與消化性疾病之因果關係
- 胃幽門螺旋桿菌的診斷與治療
頁籤選單縮合
題 名 | Serological Response to Helicobacter Pylori Infection Evaluated by Immunoblot Assay in Health Adults, Patients with Non-Ulcer Dyspepsia, Peptic Ulcer Disease, and Gastric Cancer=以免疫墨點分析法評估健康,非潰瘍性消化不良,消化性潰瘍及胃癌病患之幽門螺旋桿菌感染之血清性反應 |
---|---|
作 者 | 朱光恩; 廖朝聖; 林裕民; 王建民; 楊國卿; | 書刊名 | 中華民國消化系醫學雜誌 |
卷 期 | 17:1 2000.03[民89.03] |
頁 次 | 頁1-7 |
分類號 | 415.145 |
關鍵詞 | 西方墨點分析法; 免疫墨點分析法; 幽門螺旋桿菌; Western blot; Immunoblotting; Helicobacter pylori; |
語 文 | 英文(English) |
中文摘要 | 幽門螺旋桿菌(Hp)在胃炎、消化性潰瘍與胃癌等病變之病程中扮演的重要角色是 眾所皆知的。本研究之目的是以西方墨點法來偵測 Hp 之各種抗體反應並希望了解是否可以 藉著不同反應帶來推測可能導致何種消化道疾病。 本期瞻性研究共收集 128 病例,均經上 消化道內視鏡檢查分為下列 5 組:24 例健康者,26 例非潰疸瘍性消化不良,29 例胃潰瘍 ,32 例十二指腸潰瘍,以及 17 例胃癌者。 健康組,非潰瘍性消化不良組,及胃癌組均以 尿素脢、 Giemsa 染色、培養再進一步分為 Hp 陰性及 Hp 陽性 (三者中二者為陽性則定義 為 Hp 陽性;三者均為陰性則定義為 Hp 陰性 )。另所有消化性潰瘍患者均証實為 Hp 陽性 。 此外所有病例均以血清學分析作測試。 本研究之血清學分析採用西方免疫墨點法 (HelicoBlot 2.0, Genelabs Diagnostics, Singapore)。 在血清學上幽門螺旋桿菌之認定 要件為在色帶 116kD (CagA)、89kD(VacA)、 35kD 中之任何一處或 30kD, 26.5kD 及 19.5 kD 中二處為陽性反應。本研究結果顯示: 1). 在臺灣,由於 CagA 或 VacA 陽性菌株之盛 行率甚高, 我們無法以西方墨點法所測得之不同反應帶來預知不同的上消化道疾病。 2). 在 Hp 陰性之胃癌組病人中,仍有 89% 可於血清學分析測得 Hp 之感染, 顯示在這類病人 中, 過去可能曾經感染過 HP,由於發生萎縮性胃炎, 或小腸化生而使得 HP 不易生存,但 仍可於血清中測出曾受感染之証據。值得日後更深入探討。 |
英文摘要 | It is well known that Helicobacter pylori (H. pylori Hp) plays a role in the pathogenesis of chronic gastritis and peptic ulcer diseases. Increasing evidences emphasize the close relationship between the bacterium and gastric cancer. The aim of this study is to elucidate the pathogenic role of H. pylori in a broad spectrum ogf gastroduodenal diseases and to seek if different serological reactions to H. pylori can predict particular disease entities. A total of 138 patients were recruited in this prospective study and they were divided in five groups after receiving upper gastrointestinal endoscopic examination:Normal control; non-ulcer dyspepsia; gastric ulcer; duodenal ulcer; and gastric cancer. The normal control, non-ulcer dyspepsia and gastric cancer groups were further divided into Hp(+) and Hp(-) subgroups, while the gastric and duodenal ulcer groups were all Hp(+). Hp(+) implies positive results in at least two of the following studies:CLO test, Giemsa stain and culture, and they were all negative in the Hp(-) subgroup. the sera of the totality of patients were analyzed with the immunoblotting technique. Five reaction bands coul dbe recognized: 116 kDa (CagA), 89 kDa (VacA), 35 kDa, 30 kDa, 26.5 kDa and 19.5 kDa. Analyzing the results, the seroprevalence of the antibodies to Cag-A and VacA-positive H.pylori strain is high among the patients enrolled in this study and they are not a useful marker for screening high risk patients for a determined disease. According to this study, the immunoblot assay has no predictive value in Taiwanese patients. Interestingly, 8 out of 9 Hp(-) gastric cancer patients (89%) the immunoblot assay for the H. pylori infection was found to be positive. This finding suggests that the bacterium may not survive in a hostile gastric environment scuh as mucosa atrophy, but its remote infection is still detected in the serum by the immunoblot assay which emphasizes on the possible role of the H. pylori in the pathogenesis of gastric cancer. In addition, the sera of these 8 CA-Hp(-) patients with a positive immunoblotting were further analyzed with enzyme-immune-assay (EIA) and an interesting comparison between the two tests was done. |
本系統中英文摘要資訊取自各篇刊載內容。